MYCOBUTIN

LOE Approaching

rifabutin

NDAORALCAPSULEPriority Review
Approved
Dec 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
18

Mechanism of Action

Mechanism of Action Rifabutin inhibits DNA-dependent RNA polymerase in susceptible strains of Escherichia coli and Bacillus subtilis but not in mammalian cells. In resistant strains of E. coli , rifabutin, like rifampin, did not inhibit this enzyme. It is not known whether rifabutin inhibits…

Pharmacologic Class:

Rifamycin Antimycobacterial

Clinical Trials (5)

NCT07199452Phase 1Completed

A Study of Rifabutin and MK-4646 in Healthy Participants (MK-4646-004)

Started Oct 2025
18 enrolled
Healthy
NCT05684705Phase 1Completed

Study to Investigate the Penetration of Rifabutin Into the Lung After Multiple Intravenous Administrations of BV100

Started Sep 2023
35 enrolled
Bacterial Infections
NCT03149848Phase 1Completed

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Started Jun 2017
15 enrolled
Infection, Human Immunodeficiency VirusHIV Infections
NCT02138084Phase 1Completed

Drug-drug Interaction (DDI) Rifabutin

Started May 2014
102 enrolled
Infection, Human Immunodeficiency Virus
NCT01601626Phase 2Terminated

Rifampin-Based Tuberculosis Treatment Versus Rifabutin-Based Tuberculosis Treatment in Persons With HIV

Started Jul 2013